Form 4: Cumberland Pharmaceuticals VP Acquires Options in Company Stock
SEC Form 4 Filing
James L. Herman, VP and Chief Compliance Officer of Cumberland Pharmaceuticals, reports acquiring 2,500 options in the company's common stock.
Summary
- On March 17, 2025, James L. Herman, VP and Chief Compliance Officer of Cumberland Pharmaceuticals, acquired 2,500 options to buy common stock.
- The exercise price for these options is $5.17.
- The options become exercisable on March 17, 2029, and expire on March 17, 2035.
- Following this transaction, Herman beneficially owns 18,500 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports a transaction.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings in the company's stock.
Stakeholder Impact
- The transaction could have a minor impact on shareholders by signaling management's confidence (or lack thereof) in the company's future performance, although a small option grant is unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 03/17/2025 | Date of the transaction: acquisition of options. |
| 03/17/2029 | Date the options become exercisable. |
| 03/17/2035 | Expiration date of the options. |
| 03/18/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.